These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

145 related items for PubMed ID: 19501260

  • 21. CD4 mimetic miniproteins: potent anti-HIV compounds with promising activity as microbicides.
    Van Herrewege Y, Morellato L, Descours A, Aerts L, Michiels J, Heyndrickx L, Martin L, Vanham G.
    J Antimicrob Chemother; 2008 Apr; 61(4):818-26. PubMed ID: 18270220
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. New developments in HIV drug resistance.
    Cane PA.
    J Antimicrob Chemother; 2009 Sep; 64 Suppl 1():i37-40. PubMed ID: 19675018
    [Abstract] [Full Text] [Related]

  • 24. The role of receptors in the HIV-1 entry process.
    Jones R, Nelson M.
    Eur J Med Res; 2007 Oct 15; 12(9):391-6. PubMed ID: 17933719
    [Abstract] [Full Text] [Related]

  • 25. Quantifying the relationship between HIV-1 susceptibility to CCR5 antagonists and virus affinity for antagonist-occupied co-receptor.
    Buontempo PJ, Wojcik L, Buontempo CA, Ogert RA, Strizki JM, Howe JA, Ralston R.
    Virology; 2009 Dec 20; 395(2):268-79. PubMed ID: 19846188
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. The relative activity of "function sparing" HIV-1 entry inhibitors on viral entry and CCR5 internalization: is allosteric functional selectivity a valuable therapeutic property?
    Muniz-Medina VM, Jones S, Maglich JM, Galardi C, Hollingsworth RE, Kazmierski WM, Ferris RG, Edelstein MP, Chiswell KE, Kenakin TP.
    Mol Pharmacol; 2009 Mar 20; 75(3):490-501. PubMed ID: 19064629
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. [Antiviral action of membranotropic compounds modified by adamantane and norbornene pharmacophores exerted on different HIV-1 strains].
    Kiseleva IaIu, Perminova NG, liasunova OA, Timofeev DI, Serbin AV, Kas'ian LI, Egorov IuA, Grebinik TS, Timofeev IV.
    Mol Gen Mikrobiol Virusol; 2005 Mar 20; (2):33-6. PubMed ID: 15954475
    [Abstract] [Full Text] [Related]

  • 30. Synergistic combinations of the CCR5 inhibitor VCH-286 with other classes of HIV-1 inhibitors.
    Asin-Milan O, Sylla M, El-Far M, Belanger-Jasmin G, Haidara A, Blackburn J, Chamberland A, Tremblay CL.
    Antimicrob Agents Chemother; 2014 Dec 20; 58(12):7565-9. PubMed ID: 25267674
    [Abstract] [Full Text] [Related]

  • 31. The chemokine system and CCR5 antagonists: potential in HIV treatment and other novel therapies.
    Dhami H, Fritz CE, Gankin B, Pak SH, Yi W, Seya MJ, Raffa RB, Nagar S.
    J Clin Pharm Ther; 2009 Apr 20; 34(2):147-60. PubMed ID: 19250135
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. CD4-BFFI: a novel, bifunctional HIV-1 entry inhibitor with high and broad antiviral potency.
    Jekle A, Chow E, Kopetzki E, Ji C, Yan MJ, Nguyen R, Sankuratri S, Cammack N, Heilek G.
    Antiviral Res; 2009 Sep 20; 83(3):257-66. PubMed ID: 19559732
    [Abstract] [Full Text] [Related]

  • 34. Evaluation of the drug interaction potential of aplaviroc, a novel human immunodeficiency virus entry inhibitor, using a modified cooperstown 5 + 1 cocktail.
    Johnson BM, Song IH, Adkison KK, Borland J, Fang L, Lou Y, Berrey MM, Nafziger AN, Piscitelli SC, Bertino JS.
    J Clin Pharmacol; 2006 May 20; 46(5):577-87. PubMed ID: 16638741
    [Abstract] [Full Text] [Related]

  • 35. A novel CCR5-specific pharmacodynamic assay in whole blood using phosphoflow cytometry highlights different ligand-dependent responses but similar properties of antagonists in CD8+ and CD4+ T lymphocytes.
    Dahl ME, Berson A, Lora J, Fuentes M.
    J Pharmacol Exp Ther; 2008 Dec 20; 327(3):926-33. PubMed ID: 18753410
    [Abstract] [Full Text] [Related]

  • 36. Prospective CCR5 small molecule antagonist compound design using a combined mutagenesis/modeling approach.
    Metz M, Bourque E, Labrecque J, Danthi SJ, Langille J, Harwig C, Yang W, Darkes MC, Lau G, Santucci Z, Bridger GJ, Schols D, Fricker SP, Skerlj RT.
    J Am Chem Soc; 2011 Oct 19; 133(41):16477-85. PubMed ID: 21942640
    [Abstract] [Full Text] [Related]

  • 37. Syntheses and SAR studies of 4-(heteroarylpiperdin-1-yl-methyl)-pyrrolidin-1-yl-acetic acid antagonists of the human CCR5 chemokine receptor.
    Shankaran K, Donnelly KL, Shah SK, Guthikonda RN, MacCoss M, Mills SG, Gould SL, Malkowitz L, Siciliano SJ, Springer MS, Carella A, Carver G, Hazuda D, Holmes K, Kessler J, Lineberger J, Miller MD, Emini EA, Schleif WA.
    Bioorg Med Chem Lett; 2004 Jul 05; 14(13):3419-24. PubMed ID: 15177445
    [Abstract] [Full Text] [Related]

  • 38. Anti-HIV-1 activity of leflunomide: a comparison with mycophenolic acid and hydroxyurea.
    Schläpfer E, Fischer M, Ott P, Speck RF.
    AIDS; 2003 Jul 25; 17(11):1613-20. PubMed ID: 12853743
    [Abstract] [Full Text] [Related]

  • 39. Biological and physical characterization of the X4 HIV-1 suppressive factor secreted by LPS-stimulated human macrophages.
    Mikulak J, Gianolini M, Versmisse P, Pancino G, Lusso P, Verani A.
    Virology; 2009 Jul 20; 390(1):37-44. PubMed ID: 19447459
    [Abstract] [Full Text] [Related]

  • 40. Design, synthesis, and biological evaluation of novel 2-methylpiperazine derivatives as potent CCR5 antagonists.
    Hu S, Wang Z, Hou T, Ma X, Li J, Liu T, Xie X, Hu Y.
    Bioorg Med Chem; 2015 Mar 01; 23(5):1157-68. PubMed ID: 25638498
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.